The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study

Yuanyuan Jin; Linhu Li; Zhaoyong Yang; Mingliang Liu; Huiyuan Guo; Weiyi Shen

doi:10.18632/oncotarget.15601

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study

Yuanyuan Jin, Linhu Li, Zhaoyong Yang, Mingliang Liu, Huiyuan Guo and Weiyi Shen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:24635-24643. https://doi.org/10.18632/oncotarget.15601

Metrics: PDF 1915 views | HTML 1548 views | ?

Abstract

Yuanyuan Jin1,*, Linhu Li1,*, Zhaoyong Yang1, Mingliang Liu1, Huiyuan Guo1, Weiyi Shen2

1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

2Zhejiang Starry Pharmaceutical Co. Ltd., Xianju 317300, China

*These authors contributed equally to this work

Correspondence to:

Mingliang Liu, email: [email protected]

Weiyi Shen, email: [email protected]

Keywords: anti-tumor, synthesis, virtual screening, farnesyltransferase inhibitor

Received: December 15, 2016 Accepted: February 08, 2017 Published: February 21, 2017

ABSTRACT

Farnesyltransferase has been regarded as a promising drug target against cancer as it is critical for membrane association of several signal transduction proteins. In this study, a novel farnesyltransferase inhibitor (IMB-1406) was identified through virtual screening. It exhibits stronger potency (IC₅₀s: 6.92–8.99 μM) than Sunitinib against all of the tested cancer cell lines. Preliminary studies on mechanism reveal that IMB-1406 induces apoptosis in HepG2 cells by arresting the cell cycle at the S phase, altering anti- and pro-apoptotic proteins leading to mitochondrial dysfunction and activation of caspase-3. This anti-tumor effect is most probably related to the inhibition of farnesyltransferase as indicated by molecular docking. Overall, IMB-1406 is a novel lead compound with potent antitumor activity and deserves further structural modifications.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15601

Publication Alerts

Research Papers:

The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study

Abstract